Quotes

Back To Menu

Nippon India Pharma Fund (G) Equity - Pharma
INVEST

Plan: OPEN | Option: Growth | Sailesh Raj Bhan

16 Apr 24 | 12:00 AM

423.86 0.90 (0.21%)

  • Underperforms

    51.36%

    Return (1Y)

    underperformed by -4.03%

  • Less Volatile

    0.69%

    Standard Deviation (1Y)

    Lower than by -0.22%

  • Not so consistent

    5/12

    Months

    Has beaten

  • Value research rating

    Not Rated

Scheme Trivia

  • Reliance Pharma Fund (G) fund has been the 5th best in 5Y performance in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been given the 5th best Risk adjusted performance for the past 5Y in the Equity - Pharma category

  • Reliance Pharma Fund (G) fund has been the 8th best in the 5Y SIP performance in the Equity - Pharma category

Critical Parameters

Everyone of us wants to create wealth by investing in top funds. Have a look at the key parameters that you need to check before deciding to invest in a mutual fund.

Returns

In last 1 year Nippon India Pharma Fund (G), has underperformed its benchmark, by -4.03% (CAGR difference)

51.36%

Underperforms

This is +ve Alpha

Performance Chart for Rs

Invested in

18 Apr 2023

Risk

In last 1 year , the volatility of Nippon India Pharma Fund (G),is Lower than its benchmark, by -0.22%

0.69%

Less Volatile

Risk Meter

Peer Comparison on Risk - Return

Consistency

For 5 out of Last 12 Months, i.e 41.67% of the times It has beaten its benchmark,

Consistency Meter

Outperforming Stocks Vs. Underperforming Stocks

Based on the last 1year analysis, currently there are, 24 Stocks beating the benchmark 7 Stocks not beating the benchmark

View Stock Composition